RxDoctor Payments Data

Prabhu Deepak Kumar Udayakumar, MD

Rheumatology · Abilene, TXNPI 1679725923

Payments from drug & device makers

$1,001in general payments, 2019–2025

Across 52 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$258
  • AbbVie$147
  • GSK$145
  • E.r. Squibb & Sons, L.L.C.$103
  • Amgen$89
  • Pfizer$72
  • plus $187 from 5 others

What the payments were for

  • Food & beverage$98298%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,001 in reported general payments places this provider in the 25th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$90,482
Medicare patients
364
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab187$1,730,378
Enbrel SureclickEtanercept51$379,272
RinvoqUpadacitinib32$270,112
Cosentyx Sensoready (2 Pens)Secukinumab24$178,517
Humira(Cf)Adalimumab14$133,556
Actemra ActpenTocilizumab24$129,581
EnbrelEtanercept15$117,745
OrenciaAbatacept11$59,390
OtezlaApremilast11$55,161
Hydroxychloroquine Sulfate491$16,400
Leflunomide173$12,298
MethotrexateMethotrexate Sodium363$9,915
Prednisone411$2,560
Colchicine56$2,358
Mycophenolate Mofetil14$1,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$147$403,66846 claims
AmgenEnbrel, Otezla$89$172,90626 claims
E.r. Squibb & Sons, L.L.C.Orencia$103$59,39011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →